MediWound (NASDAQ:MDWD) Given New $25.00 Price Target at HC Wainwright

MediWound (NASDAQ:MDWD) had its price objective decreased by analysts at HC Wainwright from $28.00 to $25.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 43.27% from the stock’s current price.

Separately, StockNews.com upgraded MediWound to a “sell” rating in a research note on Monday, August 5th.

MediWound Stock Performance

Shares of NASDAQ MDWD opened at $17.45 on Wednesday. The firm has a market cap of $188.29 million, a P/E ratio of -8.08 and a beta of 0.83. MediWound has a 1 year low of $8.48 and a 1 year high of $24.00. The firm’s 50 day moving average price is $17.16 and its 200 day moving average price is $17.38.

Hedge Funds Weigh In On MediWound

Hedge funds have recently made changes to their positions in the stock. Barclays PLC increased its holdings in shares of MediWound by 311.3% during the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 8,449 shares during the last quarter. State Street Corp increased its stake in MediWound by 219.6% during the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock worth $1,197,000 after acquiring an additional 45,529 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of MediWound in the 3rd quarter worth about $212,000. Investor AB purchased a new position in shares of MediWound in the 3rd quarter worth about $15,750,000. Finally, MetLife Investment Management LLC acquired a new position in shares of MediWound in the 3rd quarter valued at about $89,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.